Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Problem Tech Solves
Tech Brief
Many of Glooko’s competitors provide apps that show people with diabetes their data but then steer them toward outside diabetes coaches. They don’t enable the diabetes patient to make their diabetes information available to the clinical delivery system so they can connect back with their personal physicians and care teams, giving them regular visibility into their diabetes progress. These solutions provide no connectivity with the primary care physician or endocrinologist that is directing the care of the person with diabetes, such that when the patient goes to their medical office appointments every few months, the physician has no idea what has been happening in the interactions with these disconnected coaching solutions. With the approval of the person with diabetes, Glooko’s remote patient monitoring solution gives the patient’s care team visibility into their diabetes health metrics on a week-to-week or even a day-to-day basis facilitating continuity of care that will help them stay healthy and thrive. This connective visibility enables physicians and the care team to help patients recognize and address any trouble spots or areas of concern in real time so they can keep their diabetes on track in a way that results in real, improved health outcomes. Providing their physician with this kind of continuous visibility into the diabetes of his young daughter, Nuala, gives Glooko employee Patrick Watkins and his family peace of mind. “Our endocrinology team uses Glooko,” Patrick says, “ nd it just helps us make sense of the enormous amount of data that comes with diabetes.”
Tech Differentiators
Glooko is a med-tech pioneer and outlier in the management of diabetes and chronic disease in that its work and technological know-how are dedicated to enhancing—not eliminating—the all-important “therapeutic alliance” between the patient and their physician. Glooko’s mission is to increase the quality and frequency of doctor-patient communications and treatment, a challenging but achievable goal amidst an era when claims are made regularly that algorithms can serve as a stand-in for doctors. While standard diabetes care allows a patient to see their HCP in office 2 to 4 times a year, Glooko’s RPM capability goes beyond standard care by providing the HCP with consistent 24/7 visibility into the patient’s diabetes progress—including between office visits. This way, the physician can intervene sooner to address health concerns when they happen, so the patient’s diabetes can be kept in better, more consistent control. Having RPM access as a supplement to—not a substitute for—quarterly office visits helps physicians keep diabetes patients on track in a way that’s difficult to achieve with office visits alone. (See answer to question 4 for clinical ROI.) In addition to clinical outcomes, Dr. Carla Demeterco-Berggren, Director of Quality in the Diabetes Clinic at Rady Children’s Hospital of San Diego says Glooko saves them “40 full workdays a year,” in staff reporting time. Glooko’s Chief Medical Officer, Dr. Mark Clements, a global expert in pediatric endocrinology, estimates Rady’s annual savings at $40,000 - $80,000 (at 2.5 minutes per patient report, per staffer).
Validation
In a real-world study Glooko conducted of 424 adults with type 2 diabetes across 11 U.S. diabetes care centers, health care professionals used Glooko’s RPM features to monitor readings patients uploaded from their glucose monitoring devices. Able to identify patients with deteriorating glucose control, providers were able to deliver timely and remote-based interventions (e.g., coaching) outside routine clinic visits. The researchers found the following significant immediate and sustained glucose improvements among patients at all three time intervals (3, 6 and 12 months from baseline; all Ps < .05): --A decrease in average glucose levels by ~12% (20 mg/dL), --An increase by ~22% in the average proportion of glucose readings within a healthy range (70-180 mg/dL), and --A decrease by ~42% in the proportion of glucose readings that were high (>250 mg/dL).* (See Figures 1-3) (*Sheng T, Babikian S, Singh V, Clements, MA. 467-P: Immediate and Sustained Trends in Glycemic Control during Remote Patient Monitoring in People with Type 2 Diabetes. Diabetes. 2021;70 [Supplement 1]. https://doi.org/10.2337/db21-467-P) In another study where the diabetes of 278 patients was managed over three months using Glooko’s RPM and as-needed coaching interventions, average blood glucose was reduced 18%, hyperglycemia decreased 12.3%, and the time patients’ glucose levels stayed within a healthy range increased 29.4%. These improvements remained consistent after 6 and 12 months of RPM.** (**Remote patient monitoring in the real world: Immediate and long-term improvements in glycemic control. Sheng, T et al. American Association of Diabetes Educators [AADE], Emerging Science Poster, 2019.)
